Recent Client Publishing Successes
Turning Doctors into Healthcare Leaders
Why Employee Retention Falls Short
In 2017, Bloom Group worked with a consulting and training company, Career Systems International (CSI), to capture its expertise on employee retention. The first step was creating what we refer to as a “keystone” document, which explained CSI’s point of view on the issue.
Let's Talk About Sex
Dede Henley is the founder and CEO of Henley Leadership Group. One of the reasons she founded Henley Leadership is because as a younger woman she experienced sexual harassment on the job and didn't want a career that left her vulnerable to the predations of male bosses. Recently, Henley became a Forbes contributor, writing about how leaders can create healthy, productive organizational cultures in which what happened to her won't (and can't) happen to others.
Harnessing Your Boardroom Fears
This is FMG Leading’s second Harvard Business Review article. Published in October 2017, the authors CEO Matt Brubaker and Chairman Foster Mobley explain four fears they've seen hold many executives back from reaching their potential: of being wrong, of not being good enough, of missing out, and of being taken advantage of. They explain how executives can harness these fears and become far more effective leaders.
AI's Value is More Than Replacing People
Satya Ramaswamy is senior vice president of digital enterprise services at Tata Consultancy Services, the $16 billion global IT services and consulting firm. In April 2017, he published his third article in four years, "How Companies Are Already Using AI," in the Harvard Business Review, based on research that TCS conducted on how big companies around the world are using artificial intelligence. (Bloom Group has helped Satya and TCS place all three articles.)
Why Soda Taxes Won't Solve Obesity
In May 2017, Forbes.com's Leadership section published "How A Billion Dollars Is Being Wasted In The War On Sugar," an article by our client Hank Cardello of the Hudson Institute. It was Cardello's 21st Forbes.com article since 2012. The Bloom Group has helped him with all of them.
Avoiding an Expensive Mistake
According to Bain & Co. half the private equity firms it studied had replaced the CEOs of their portfolio companies, and more than half (60%) hadn’t planned to. That means those PE firms had made a big, fat, expensive mistake. Bloom Group client FMG Leading, a human capital advisory firm, has developed a proprietary process for assessing the potential of CEOs for PE firms, and in Sept.
Keys to Mitigating Risk in Adaptive Trials
Phase III trials, the last before a drug is submitted to a regulatory agency for approval, cost about $20 million. The fact that about 50% of them fail is a big problem. Sy Pretorius, Chief Scientific Officer of PAREXEL, a leading global pharmaceutical consulting firm, believes this high rate of failure is caused by traditionally rigid trial designs. He argues that designs that enable trials to change as new data is collected can reduce failures. We helped Pretorius publish his article, "Three Keys to Mitigating Risk in Adapative Trials," in Life Science Leader.
New Drug Submission Rules: A How-To
The FDA has mandated that by May 2017 all new drug applications must be submitted electronically in a format called eCTD. For drug developers to comply, they will need new tools, workflows, and publishing strategies.
Cisco’s Innovation Secrets
Gartner predicts that by 2020 there will be 21 billion things in the Internet of Things. Figuring out how all those things will share and process data, how they will be made secure, and how platforms and architectures can be built that will allow them to work together requires rapid, industrialized innovation. Bloom Group helped Cisco Systems Corporate Director Stephan Monterde share some of his company’s strategies for accelerating innovation in “How We Think About Innovation at Cisco” for HBR.org.
How to De-Risk Complex Molecule Formulation
If formulation problems surface late in the process of turning active pharmaceutical ingredients (APIs) into beneficial drugs, developers may have to change their API production processes, or even redo Phase I and Phase II trials.
The Perils of Underpricing New Products
Simon-Kucher & Partners, a $200 million+ management consulting firm specializing in marketing, sales and pricing strategies, asked us in 2015 to turn its product innovation expertise into a book. After finding an agent and helping the authors, Madhavan Ramanujam (an SKP partner) and Georg Tacke (co-CEO), capture their ideas in a manuscript, Bloom Group worked with SKP in 2016 to market the book (Monetizing Innovation: How Smart Companies Design the Product Around the Price) through two HBR.org articles. This, the second article (“Your New Hit Product Might Be Underpriced”), ran in the publication’s May 24, 2016 online edition.
Innovation Lessons from Porsche and Fiat Chrysler
The first of two Harvard Business Review articles Bloom Group helped Simon-Kucher & Partners' Madhavan Ramanujam and Georg Tacke prepare to publicize their book Monetizing Innovation. “In Product Development, Let Your Customers Define Perfection” compares the launch of Porsche's Cayenne SUV in the early 2000s and Fiat Chrysler’s Dodge Dart about 10 years later. The Cayenne became a huge hit; the Dart flopped. The article, which ran in the May 9, 2016 online edition of HBR, explains why.
Simon Kutcher & Partners (SKP) is a global management consulting firm.
Speeding Drugs to Market
The FDA is creating new pathways to shorten the time it takes for new medicines to receive regulatory approval. However, meeting FDA requirements for these pathways can be a tricky business. PAREXEL is a leading international drug consulting firm, and Bloom Group helped PAREXEL Vice President Barry Farrimond, Network for Excellence in Health Innovation President Jonathan Fleming, and PAREXEL expert Mark Mathieu place their article “FDA’s Accelerated Pathways Are the New Normal” in DIA, the publication of the Drug Information Association.
The National Football League and Its Attackers
Hudson Institute Senior Fellow Hank Cardello weighs in on the latest round between the NFL and the growing number of activists who are attacking its stand on concussions. In his latest Forbes.com post, Cardello suggests that the NFL should recognize those who are railing against it as an important market segment, not as a parariah.
Waste-Not Want-Not Formulation and Process Design
Developers must make important decisions about product formulation and process design to move a drug from preclinical through Phase II trials as quickly as possible. Over-engineering a Phase I or Phase II drug that ultimately fails in the clinic wastes resources. But neglecting sound science during early stages can result in a promising product that may not have a scalable or commercially manufacturing process.
Asian Supply Chain Mysteries
An Oregon woman opens a box of Halloween decorations she bought at her local K-Mart and out falls a note pleading for help, written by a man in a Chinese prison camp. How does this happen? According to FTI Consulting Forensic & Litigation Consulting Senior Director Greg Hallahan, Western companies that outsource manufacturing to Asia do a pretty good job vetting their suppliers, but not such a good job checking to see if their suppliers are subcontracting the work out. We helped Hallahan repurpose his article in FTI Journal, for Thomson Reuters News and for Supply & Demand Chain Executive.
Innovation Goes Better At Coke
Bloom Group has assisted Brad Power, a Partner at advisory, educational, and research firm FCB Partners, publish many articles in many journals, including Forbes.com. Here, in "How Coca-Cola Uses Entrepreneurs (and Keurig) to Jump-Start Innovation," Power reports on the company's arm's-length-yet-nurturing approach to start-ups, which enables it to incorporate innovation into its business processes without stifling it with process bureaucracy.
Solving for Solubility
Solubility is a key issue when formulating drugs for manufacture, and the proportion of new drugs that are hard to dissolve has been increasing. There are lots of formulation technologies available to drug manufacturers to address solubility, but it’s not always easy to know which one is best for a new drug.
Fighting Pharma Demand Forecast Fails
Given the long road drugs must travel to get to market, developers have to predict demand, and line up production capacity, years before a new product launches. If they guess too low, they won’t have enough to meet demand (causing reputational damage and the loss of potential revenue). If they guess too high, they’re stuck with product they can’t sell.
Taking Coke and Its Attackers to Task
Coca-Cola Co. has made lots of headlines in the summer and fall of 2015, not all of them good. The company was criticized for not disclosing its investments in health organizations and health research initiatives. In his latest post for Forbes.com (“Shame Is a Losing Strategy for Both Coke And Its Attackers”), our client Hank Cardello (head of the Obesity Solutions initiative at the Washington, D.C., think-tank the Hudson Institute) discusses the criticism lobbied against Coke, and why the beverage giant’s new transparency about who it funds is good but not good enough. You can read his article (published in September) here.
Fighting Bribery and Fraud in Emerging Markets
Matías Mora Simoes is a Senior Managing Director in the FTI Consulting Forensic and Litigation Consulting practice and is the head of the FTI Consulting Panama and FTI Consulting Mexico offices. We helped him place his article, “What Companies Do Right (and Wrong) Fighting Bribery and Fraud in Emerging Markets,” based on FTI Consulting research, in Corporate Compliance Insights. You can read the article, here.
Avoiding Risk in Emerging Markets: A Study
The Bloom Group helped FTI Consulting, an international business advisory firm, conduct a quantitative and qualitative survey of global business leaders to discover how leading companies successfully mitigated the many risks of doing business in emerging markets, and what laggard companies were doing wrong. We then helped FTI Consulting’s senior leaders publish the survey’s findings, and many articles derived from them, in several executive journals, including the online edition of The Harvard Business Review, Risk Management Monitor, Corporate Compliance Insights, and CFO.com.
Mighty Midsized Companies
Big Food's Collaboration Lessons for Congress
Our client Hank Cardello of the Hudson Institute writes in his latest guest commentator post for Forbes.com about what Washington could learn from the food industry on how to work with anti-industry activitists. Through a number of initiatives, the food industry and many of its critics have found common ground in the fight against obesity and for healthier food. You can read Hank's article here.
The How and Why of Telemedicine
The use of telemedicine is on the rise; it's benefits are obvious to patients and providers, but there remain social and regulatory hurdles to surmount. We helped FTI Consulting Senior Managing Director Wayne Gibson, and FTI Consulting Health Solutions Managing Director Jeffrey Bessette suggest ways to leap those hurdles in "The How and Why of Telemedicine," published in Health Management Technology.
Oil and Gas Industry Gets Social Media Wrong
Steve Everley is a Senior Director at FTI Consulting, advising clients in a broad range of industries, including coal, refining and LNG exports. Everley published an article in FTI Journal, “Drilling for a Social Media Strategy,” here, about how social media, which can target small groups and communicate with them in an intimate manner, is a better communication channel for the oil and gas industry than the national marketing efforts it has heretofore focused upon. The industry has left social media to its activist opponents. It can do so no longer.
In December, we helped Everley publish a version of his FTI Journal article in industry publication OGI, here.
Taking Business School Research Out of the Ivory Tower
Why studies need to be much more relevant to corporations, and how to do so.
Restaurants and the Obesity Epidemic
In this Forbes.com guest commentary, Hudson Institute consultant Hank Cardello takes the U.S. restaurant industy to task. The industry’s shortcoming? Failing to regard the nation’s obesity epidemic seriously enough, as both a social problem and an economic opportunity.
The article (“Restaurants Should Be Doing More to Fight Obesity – for Their Own Good”) ran on Dec. 22 in Forbes.com’s Leadership section. You can read it here. We helped Cardello with the piece, as well as 20 other Forbes.com articles in the last two years.
Why the Oil and Gas Industry Can’t Ignore Social Media
It’s increasingly important to obtaining a license to operate.
Stopping Counterfeiting: A Better Way
The problem of counterfeit goods is global and the cost is high. Most companies fight back by trying to catch the street vendors. FTI Consulting Senior Managing Director Bob Youill has a better idea: focus on the companies that package the counterfeit goods and get more bang for your buck. We helped Youill write an article for FTI Journal, "How to Counter the Counterfeiters," following which the Wall Street Journal interviewed Youill at length for the article "High-Tech Packaging Fights Counterfeiters."
Catch-22 in Asian eDiscovery
Richard Kershaw is a Managing Director and leader in the Technology practice of FTI Consulting. In June 2014, the Bloom Group helped Kershaw publish an article in FTI Journal here, identifying the problem U.S. and European companies face when they try to collect information in Asia to comply with requests from their home regulators.
Shortly after the FTI Journal article appeared, the Wall Street Journal published a commentary in its “Morning Risk Report” here focusing on the problem Kershaw identified, quoting him extensively.
Balanced Healthcare Transformation
How payers and providers can reduce costs while improving care.
Growing a Midsize Business, Wrongly
Robert Sher, who Bloom Group helped write and publish Mighty Midsized Companies, spun off a series of articles based on his book for HBR.org. In "How Midsized Companies Can Avoid Fatal Acquisitions," Sher discusses how dreams of growth-through-acquisition can turn into nightmares, and provides case examples of strategies midsized companies can employ to do a better job of sizing up opportunities.